<mediadc-video-embed data-state="{"cms.site.owner":{"_ref":"00000161-3486-d333-a9e9-76c6fbf30000","_type":"00000161-3461-dd66-ab67-fd6b93390000"},"cms.content.publishDate":1656176377568,"cms.content.publishUser":{"_ref":"00000174-20cd-dd98-a5fd-64dfb14c0003","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"cms.content.updateDate":1656176377568,"cms.content.updateUser":{"_ref":"00000174-20cd-dd98-a5fd-64dfb14c0003","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"rawHtml":"
var _bp = _bp||[]; _bp.push({ "div": "Brid_56176232", "obj": {"id":"27789","width":"16","height":"9","video":"1027703"} }); ","_id":"00000181-9bcd-d789-a3f7-9beffa190000","_type":"2f5a8339-a89a-3738-9cd2-3ddf0c8da574"}”>Video EmbedPfizer announced Saturday that tweaking its COVID-19 vaccine to better target the omicron variant is safe and works — just days before regulators debate whether to offer people updated booster shots this fall.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
Already a member? Log in
